Streetbeat News

Price Targets

LLY

Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Eli Lilly (NYSE:LLY) and maintained a price target of $550.

Portfolio Pulse from richadhand@benzinga.com

July 17, 2023 | 1:53 pm

HAL

Morgan Stanley analyst Connor Lynagh has reiterated an Overweight rating on Halliburton (NYSE:HAL) and maintained a $45 price target.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 1:52 pm

VRCA

HC Wainwright & Co. analyst Oren Livnat has reiterated a 'Buy' rating on Verrica Pharmaceuticals (NASDAQ:VRCA) and maintained an $11 price target.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 1:52 pm

ACAD

Cantor Fitzgerald analyst Sarah James maintains an Overweight rating on ACADIA Pharmaceuticals and raises the price target from $36 to $42.

Portfolio Pulse from richadhand@benzinga.com

July 17, 2023 | 1:52 pm

BHVN

Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Biohaven (NYSE:BHVN) and maintained a price target of $31.

Portfolio Pulse from richadhand@benzinga.com

July 17, 2023 | 1:51 pm

GDRX

Morgan Stanley analyst Ricky Goldwasser maintains an Equal-Weight rating on GoodRx Holdings (NASDAQ:GDRX) and raises the price target from $6 to $8.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 1:51 pm

ABOS

Cantor Fitzgerald analyst Pete Stavropoulos has reiterated an Overweight rating on Acumen Pharmaceuticals (NASDAQ:ABOS) and maintained a $13 price target.

Portfolio Pulse from richadhand@benzinga.com

July 17, 2023 | 1:51 pm

RMTI

HC Wainwright & Co. analyst Raghuram Selvaraju maintains a 'Buy' rating on Rockwell Medical (NASDAQ:RMTI) and raises the price target from $9 to $11.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 1:51 pm

ARAV

Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Aravive (NASDAQ:ARAV) and maintained a price target of $18.

Portfolio Pulse from richadhand@benzinga.com

July 17, 2023 | 1:50 pm

GMAB

Morgan Stanley analyst Matthew Harrison has reiterated an 'Underweight' rating on Genmab (NASDAQ:GMAB) and maintained a $33 price target.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2023 | 1:49 pm